China Medipharm Insights - Issue No. 34 - March 1999

 

Regular Price: USD 1,000

Special Price USD 700

30% OFF

* Required Fields

Regular Price: USD 1,000

Special Price USD 700

PAY BY INVOICE

Be the first to review this product

Table of Contents

China Medipharm Insights - Issue No. 34 - March 1999, THE YEAR IN REVIEWREGULATORY DEVELOPMENTS OVERSHADOWED OTHER EVENTS IN CHINA'S PHARMA MARKET IN 1998CMI’s Review of 1998VIEWPOINTSWind of ChangeCOMPANY PROFILESanofi-Synthelabo Enlarges Investment in ChinaTopical Drug Production Center EstablishedXinhua Chemferm To Be the Largest Cephalosporin SupplierBMS (China) Investment Co. EstablishedShanghai Pharmaceutical Industry Co. Ltd.Reported 59% Increase in ExportMeihe Jinyi Bioengineering Co. OperatedWeiming Group Constructing Peking University Bio-CityLukang Group Acquired Jining No.3 PharmaShijiazhuang Group DevelopsNorth China Became Largest Chinese Semi-Synthetic Antibiotics ProducerRuide Pharma’s Technical Innovation Project ApprovedAmikacin Sales Center of Shanghai Pharma Group Ran WellMinsheng Saw Sales of US$59 Million in Jan-NovAnte Pharma Disconnects its Military TiesGuangzhou Medicine Group Saw 14% Increase in Profit in Jan-OctTongji Pharma Acquires Wuhan No. 6 PharmaShanhe Group Reported 84% Increase in Profit in 1998Jiangshan Pharma Passed ISO9002 CertificationPRODUCT NEWSR&D of New Drugs in China Shows Good ProspectNew Antibiotic Etimicin Approved for ProductionClarithromycin DevelopedAzithromycin Dispersion Tablet LaunchedAnti-Cancer New Drugs DevelopedHOSPITAL DRUG CONSUMPTIONAnalysis of Drug Consumption in Shanghai Hospitalsin the Third Quarter in 1998NEWS IN BRIEFPhRMA Expresses Objection to Chinese AmbassadorNew Drug Pricing Plan to be Issued in MarchSETC Determined Working Emphasis on Medicines for 1999Community Healthcare Services Established in Many CitiesChina Pharmaceutical Industry Saw 14% Growth in Output in 1998New GMP Standards to be ImplementedTwo New Drug Centers Established in ShanghaiOverdue Drugs to be Cleared OutGenetic Engineering Trial Production Center EstablishedTen Important News Items in China’s Medicine Sector in 1998China’s “Biomedicine Engineering Industrial Program” StartedDrug Evaluation Center Will Evaluate the Me-Too DrugsGrowth Rate of Free Healthcare Expenses Reduced in BeijingZhejiang Medical Economy Increased at High Speedin the First Nine Months in 1998China Hepatitis Prevention Foundation Set UpParkinson’s Disease Treatment Center EstablishedGuangdong Limits Hospital Income by DrugsTianjin and Shanghai Reduced Drug PricesChina’s Human Genome Research Made Great ProgressesDNA Chip Gene Sequencing Technology DevelopedHebei Drug Administration Formed




Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.